Lidocaine’s potential role in treating head and neck squamous cell carcinoma
Lidocaine, a common local anesthetic, has been found to induce apoptosis in head and neck squamous cell carcinoma (HNSCC) by activating the bitter taste receptor T2R14. This activation triggers intracellular calcium mobilization, mitochondrial depolarization, and reactive oxygen species (ROS) production, ultimately leading to cell death. Additionally, lidocaine’s ability to inhibit the ubiquitin-proteasome system through T2R14 further contributes to its anti-cancer effects. The findings suggest that lidocaine could be repurposed as a therapeutic agent, particularly for HPV-positive HNSCCs, where T2R14 expression is elevated.
https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01449-3
Lidocaine, a common local anesthetic, has shown potential in targeting cancer cells beyond its traditional use. Researchers are exploring how lidocaine can influence cancer cell behavior, including reducing metastasis, slowing cell division, and even inducing cell death. This emerging field of study suggests that lidocaine might serve as a complementary therapy in cancer treatment, especially during surgeries, by not only providing pain relief but also by directly impacting cancer cell viability.
0 Comments